JP2007525503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525503A5 JP2007525503A5 JP2007500824A JP2007500824A JP2007525503A5 JP 2007525503 A5 JP2007525503 A5 JP 2007525503A5 JP 2007500824 A JP2007500824 A JP 2007500824A JP 2007500824 A JP2007500824 A JP 2007500824A JP 2007525503 A5 JP2007525503 A5 JP 2007525503A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- aliphatic
- disease
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 75
- 239000000203 mixture Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000001412 amines Chemical class 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- -1 1,2-methylenedioxy Chemical group 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 4
- 229930192474 thiophene Natural products 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000035690 Familial cold urticaria Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019773 Hepatitis G Diseases 0.000 claims 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100039898 Interleukin-18 Human genes 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000001187 pylorus Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 CC(C1)C(O*)OC1=O Chemical compound CC(C1)C(O*)OC1=O 0.000 description 3
- OMTPLIZMNOGTKO-UHFFFAOYSA-N CCC1N2C1(C)C1CCC2CC1 Chemical compound CCC1N2C1(C)C1CCC2CC1 OMTPLIZMNOGTKO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54861004P | 2004-02-27 | 2004-02-27 | |
| US62974304P | 2004-11-19 | 2004-11-19 | |
| US62966104P | 2004-11-19 | 2004-11-19 | |
| PCT/US2005/006540 WO2005085236A2 (en) | 2004-02-27 | 2005-02-28 | Caspase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011095553A Division JP2011144203A (ja) | 2004-02-27 | 2011-04-21 | カスパーゼインヒビターおよびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525503A JP2007525503A (ja) | 2007-09-06 |
| JP2007525503A5 true JP2007525503A5 (https=) | 2008-04-03 |
Family
ID=34923260
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500824A Pending JP2007525503A (ja) | 2004-02-27 | 2005-02-28 | カスパーゼインヒビターおよびそれらの使用 |
| JP2011095553A Withdrawn JP2011144203A (ja) | 2004-02-27 | 2011-04-21 | カスパーゼインヒビターおよびそれらの使用 |
| JP2014097786A Pending JP2014140385A (ja) | 2004-02-27 | 2014-05-09 | カスパーゼインヒビターおよびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011095553A Withdrawn JP2011144203A (ja) | 2004-02-27 | 2011-04-21 | カスパーゼインヒビターおよびそれらの使用 |
| JP2014097786A Pending JP2014140385A (ja) | 2004-02-27 | 2014-05-09 | カスパーゼインヒビターおよびそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7652153B2 (https=) |
| EP (2) | EP1718639A2 (https=) |
| JP (3) | JP2007525503A (https=) |
| KR (1) | KR20060129069A (https=) |
| CN (1) | CN102161656B (https=) |
| AR (1) | AR047981A1 (https=) |
| AU (1) | AU2005219861B2 (https=) |
| BR (1) | BRPI0508102A (https=) |
| CA (1) | CA2557645C (https=) |
| IL (1) | IL177709A0 (https=) |
| NO (2) | NO20064344L (https=) |
| NZ (1) | NZ549665A (https=) |
| RU (1) | RU2382780C2 (https=) |
| TW (2) | TWI362381B (https=) |
| WO (1) | WO2005085236A2 (https=) |
| ZA (1) | ZA200607634B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1064298T3 (da) * | 1998-03-19 | 2009-01-19 | Vertex Pharma | Inhibitorer af caspaser |
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| SG150547A1 (en) * | 2004-03-12 | 2009-03-30 | Vertex Pharma | Processes and intermediates |
| MXPA06013256A (es) * | 2004-05-15 | 2007-02-08 | Vertex Pharma | Tratamiento de crisis convulsivas utilizando inhibidores ice. |
| CA2567080A1 (en) * | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| WO2011094426A1 (en) * | 2010-01-29 | 2011-08-04 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Caspase inhibitors |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| ES2751652T3 (es) | 2014-05-12 | 2020-04-01 | Conatus Pharmaceuticals Inc | Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| JP2019500397A (ja) | 2015-12-31 | 2019-01-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤を肝疾患の治療に使用する方法 |
| CN105853408B (zh) * | 2016-04-15 | 2018-12-04 | 浙江大学 | 苯酰胺衍生物在制备Caspase-1抑制剂中的应用 |
| RU2019113150A (ru) | 2016-10-05 | 2020-11-06 | Новартис Аг | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| US20260062443A1 (en) * | 2022-08-23 | 2026-03-05 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| GB9005014D0 (en) * | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| KR100381584B1 (ko) * | 1994-07-22 | 2003-08-21 | 알타나 파마 아게 | 디히드로벤조푸란 |
| FI974437A7 (fi) * | 1995-06-06 | 1997-12-05 | Pfizer | Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina |
| KR20000036056A (ko) * | 1996-09-12 | 2000-06-26 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | 인터루킨-1β 전환 효소 및 관련 프로테아제의 억제제로서의 Ｃ-말단 변형된 (Ｎ-치환된)-2-인돌릴 디펩티드 |
| EP0929311B8 (en) * | 1996-09-12 | 2006-02-01 | Idun Pharmaceuticals, Inc. | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS |
| FR2766188B1 (fr) | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
| DK1064298T3 (da) * | 1998-03-19 | 2009-01-19 | Vertex Pharma | Inhibitorer af caspaser |
| US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| ES2322538T3 (es) | 1999-01-29 | 2009-06-23 | Senju Pharmaceutical Co., Ltd. | Inhibidores contra el aumento de la tension ocular causada por irradiacion con laseres, que contienen derivados de 1,4-dihidropiridina. |
| CA2402128A1 (en) | 2000-04-24 | 2001-11-01 | Vertex Pharmaceuticals Incorporated | Process and intermediates for making substituted aspartic acid acetals |
| PE20011350A1 (es) * | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| TR200200767T1 (tr) | 2000-05-23 | 2002-09-23 | Vertex Pharmaceuticals Incorporated | Kaspaz engelleyiciler ve kullanımları |
| EP1289993B9 (en) | 2000-06-07 | 2008-08-20 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2002022611A2 (en) | 2000-09-13 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| US20030096737A1 (en) | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| US6645994B1 (en) | 2001-06-01 | 2003-11-11 | Alcon, Inc. | Method of treating dry eye disorders |
| US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
| SG150547A1 (en) * | 2004-03-12 | 2009-03-30 | Vertex Pharma | Processes and intermediates |
-
2005
- 2005-02-28 EP EP05724143A patent/EP1718639A2/en not_active Withdrawn
- 2005-02-28 CA CA2557645A patent/CA2557645C/en not_active Expired - Fee Related
- 2005-02-28 BR BRPI0508102-5A patent/BRPI0508102A/pt not_active IP Right Cessation
- 2005-02-28 CN CN2010106215884A patent/CN102161656B/zh not_active Expired - Fee Related
- 2005-02-28 AR ARP050100737A patent/AR047981A1/es unknown
- 2005-02-28 US US11/069,895 patent/US7652153B2/en not_active Expired - Fee Related
- 2005-02-28 JP JP2007500824A patent/JP2007525503A/ja active Pending
- 2005-02-28 WO PCT/US2005/006540 patent/WO2005085236A2/en not_active Ceased
- 2005-02-28 KR KR1020067019903A patent/KR20060129069A/ko not_active Ceased
- 2005-02-28 RU RU2006134258/04A patent/RU2382780C2/ru not_active IP Right Cessation
- 2005-02-28 AU AU2005219861A patent/AU2005219861B2/en not_active Ceased
- 2005-02-28 NZ NZ549665A patent/NZ549665A/en not_active IP Right Cessation
- 2005-02-28 EP EP10013186A patent/EP2270004A1/en not_active Withdrawn
- 2005-03-01 TW TW094106099A patent/TWI362381B/zh not_active IP Right Cessation
- 2005-03-01 TW TW101100244A patent/TW201217332A/zh unknown
-
2006
- 2006-08-27 IL IL177709A patent/IL177709A0/en not_active IP Right Cessation
- 2006-09-12 ZA ZA2006/07634A patent/ZA200607634B/en unknown
- 2006-09-26 NO NO20064344A patent/NO20064344L/no unknown
- 2006-09-26 NO NO20064351A patent/NO20064351L/no not_active Application Discontinuation
-
2009
- 2009-12-03 US US12/630,350 patent/US20100105914A1/en not_active Abandoned
-
2011
- 2011-04-21 JP JP2011095553A patent/JP2011144203A/ja not_active Withdrawn
-
2014
- 2014-05-09 JP JP2014097786A patent/JP2014140385A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533825A5 (https=) | ||
| JP2007525503A5 (https=) | ||
| RU2005102094A (ru) | Ингибиторы каспазы и их применение | |
| FI91151C (sv) | Förfarande för framställning av farmaceutiskt aktiva bensimidazolföreningar | |
| CA2067221C (en) | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient | |
| JP2003535865A5 (https=) | ||
| DE69913047T2 (de) | Verfahren zur Herstellung von Benzamid-Derivaten | |
| JP2003534325A5 (https=) | ||
| JP2006513220A5 (https=) | ||
| CA2479103A1 (en) | 1-azabicyclic n-biarylamides with affinity for the alpha7 nicotinic acetylcholine receptor | |
| JP2002514649A (ja) | エポチロン誘導体、それらの製造方法、並びにそれらの使用 | |
| JP2005505618A5 (https=) | ||
| JPS62198683A (ja) | 置換チエノイミダゾ−ル誘導体およびその製法 | |
| RU2006134258A (ru) | Ингибиторы каспаз и их применение | |
| CA2156961A1 (en) | Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as medicaments | |
| DE69128477T2 (de) | Benzopyranderivat | |
| JPH06500085A (ja) | ベンズイミダゾール、その製造および使用法 | |
| CA2076982A1 (en) | Pyridonecarboxylic acid derivatives | |
| AU733096B2 (en) | Cyanoguanidines as cell proliferation inhibitors | |
| CN111233750A (zh) | 一种3,3-二氟-1,2,3,6-四氢哌啶类衍生物及其制备方法 | |
| JP2719841B2 (ja) | チオ尿素誘導体及びその製造方法 | |
| JPS5810583A (ja) | ５，６，７，７ａ−テトラヒドロ−４Ｈ−チエノ（３，２−ｃ）−ピリジン−２−オン誘導体の製法 | |
| NZ232135A (en) | Cephemcarboxylic acid ester derivatives and pharmaceutical compositions | |
| US20090227645A1 (en) | Pharmaceutical compositions of valdecoxib | |
| JP5127114B2 (ja) | Ｃｆ３−ｃｈｆ−ｃｆ２−ｎｒ２合成方法 |